Browsed by
Month: June 2023

Quick guide on Metabolic-associated fatty liver disease.

Quick guide on Metabolic-associated fatty liver disease.

Comments 0 Comment

According to researchers, the prevalence of metabolic-associated fatty liver disease is sharply rising in the US.

Although there are other causes, experts say heredity and fat are the two main contributors to the disease. They claim that a balanced diet and regular exercise can help lower the risk of contracting the illness.

The most common cause of liver disease worldwide and one that is notably rising in the US is metabolic-associated fatty liver disease (MAFLD), formerly known as nonalcoholic fatty liver disease.

That is supported by a study that was presented today at ENDO 2023, the annual conference of the Endocrine Society.

Researchers examined data for 32,726 National Health and Nutrition Examination Survey participants in their findings, which have not yet been published in a peer-reviewed journal.

They gathered health data between 1988 and 2018.

The investigators contrasted rising MAFLD rates with rising obesity rates. They claimed that

  • From 16% of participants in 1988 to 37% in 2018, there has been a 131% increase in MAFLD.
  • From 23% in 1988 to 40% in 2018, there was a 74% increase in the prevalence of obesity.

MAFLD risk factors

Prior to this, medical experts believed that obesity was the main risk factor for MAFLD.

Because MAFLD grew more quickly than fat, the researchers hypothesised that there must be additional risk factors, such as diabetes and hypertension.

The incidence rate for each of the three studied population groups considerably rose during the course of the study:

  • Whites: 133%
  • among Mexican Americans, 61%
  • 60% of Blacks

Mexican Americans consistently had a greater rate of MAFLD than the general population did over the course of the study.

Dr. Aymin Delgado-Borrego, a hepatologist of KIDZ Medical who was not involved in the study, noted that Hispanics/Latinos have a higher prevalence of MAFLD.

She informed us that because Latinos from Mexico and Central America are more common than those from other countries, it is not appropriate to generalise this to all Hispanics.

But even though Hispanics are more frequently impacted, the study’s key result is that non-Hispanic whites had a more significant rise in prevalence. Once more, this is crucial information that can be used to comprehend the various contributing variables of MAFLD, according to hepatologist Dr. Aymin Delgado-Borrego.

Many forms of fatty liver disease

Alcoholic and nonalcoholic fatty liver diseases are the two main varieties.

Although it’s rare, fatty liver can also occur during pregnancy.

Nonalcoholic fatty liver disease (NAFLD)

Fat deposits in the liver of non-heavy drinkers are known as non-alcoholic fatty liver disease (NAFLD).

NAFLD may be diagnosed if you have too much fat in your liver and no history of drinking heavily. Simple NAFLD is the name given to the disorder if there is no inflammation or other problems.

NAFLD includes non-alcoholic steatohepatitis (NASH). It occurs when inflammation coexists with the accumulation of extra fat in the liver. A physician may identify NASH if:

  • Your liver has too much fat.
  • You have an irritated liver.
  • You’ve never consumed a lot of booze before.

In the absence of treatment, NASH can result in liver fibrosis. This might worsen in extreme cases, leading to cirrhosis and liver failure.

Alcoholic fatty liver disease (AFLD)

Abundant alcohol use harms the liver. The initial stage of alcohol-related liver damage is known as alcoholic fatty liver disease (AFLD). The condition is referred to as simple alcoholic fatty liver if there is no inflammation or other problems.

An example of AFLD is alcoholic steatohepatitis (ASH). It is sometimes referred to as alcoholic hepatitis and occurs when there is an accumulation of extra fat in the liver along with inflammation. A physician could identify Trusted Source ASH if:

  • Your liver has too much fat.
  • You have an irritated liver.
  • You partake in heavy drinking

If left untreated, ASH can result in liver fibrosis. Cirrhosis, a severe liver scarring condition, can cause liver failure.

Acute fatty liver of pregnancy (AFLP)

When too much fat accumulates in the liver during pregnancy, it is known as acute fatty liver pregnancy (AFLP). It’s a dangerous pregnancy issue that is uncommon. Genetics may play a role, albeit the precise cause is uncertain.

AFLP typically manifests during the third trimester of pregnancy. It poses significant health concerns to the mother and child if left untreated.

A doctor will want to deliver your baby as soon as possible if they diagnosis AFLP. After giving delivery, you might require follow-up treatment for a few days.

After delivering delivery, your liver’s health should return to normal in a few weeks.

Relating to fatty liver disease caused by a metabolic disorder

A 2020 study found that the term “metabolic-associated fatty liver disease” refers to a range of liver conditions that are not directly related to alcohol consumption.Published in the World Journal of Hepatology.

One of the main justifications for liver transplants is MAFLD. Currently, it is the main contributor to liver disease worldwide.

Dr. Hillel Tobias, a specialist in transplant hepatology, gastroenterology, and internal medicine at Northwell Lenox Hill Hospital in New York who was not involved in the study, stated that “in 2015 and earlier, [viral] hepatitis was the most prevalent cause of liver disease.”

He explained to us that MAFLD rose to become the leading cause once medications to treat viral hepatitis were discovered.

MALFD symptoms and causes

According to the National Institutes of Health, MALFD is a quiet disease because it exhibits little to no symptoms. Fatigue or soreness in the upper right side of the abdomen may be experienced by those with symptoms.

Genes are one factor in MAFLD. Mexican Americans are thought to be genetically predisposed to the condition, making them more prone to suffer from it.

Additional factors include:

  • obesity or excess weight
  • glucose intolerance or type 2 diabetes
  • abnormal blood fat levels, including high triglycerides, high cholesterol, and low HDL
  • Large waist circumference, high triglyceride levels, low HDL, high blood pressure, high blood glucose, or type 2 diabetes are all symptoms of the metabolic syndrome.

Currently, researchers are looking into a potential connection between MALFD and fructose-heavy diets. Additionally, they are investigating any potential impacts of the gut microbiota.

Diet may contribute to MAFLD.

The National Institutes of Health (NIH) reports that research has connected various environmental pollutants to fatty liver disease.

Household chemicals like vinyl chloride, which is used to make PVC, as well as others, may be a factor.

“Some people are predisposed to MAFLD, as shown by the high incidence rate in Hispanics,” Dr. Hillel added.

“This is somewhat explained by the significant dietary differences between Mexico and the United States. The high prevalence may be related to switching from one eating pattern to another because the American diet contains far more carbs. A diet rich in carbs can cause fatty liver.

“COVID-19 may also have contributed to the higher rates because people’s diets changed when they were all confined to their homes,” says the researcher. added Dr. Hillel. Although many people began eating healthier, many still turned to processed and fast foods, which are rich in carbs.

Dr. Hillel stated, “Overall, although I somewhat agree with the results, this was not really a good study. “We need to see the results repeated and supported by additional research,”

lowering the danger of fatty liver illness

MALFD can be reversed if caught early, according to doctors, because the liver is capable of self-repair. However, because it is a silent disease (or at least one that is very quiet), it is not frequently found early.

Imaging exams and blood testing can reveal the disease. Only a biopsy can determine whether the disease has reached a hazardous stage.

Dr. Lisa Ganjhu, a gastroenterologist and hepatologist at NYU Langone Health in New York who was not involved in the study, told us that if it is not treated, it could turn into cirrhosis. However, there are measures to lower your chance of contracting the illness.

According to Caroline Thomason, a nutritionist with a practise in Virginia who was not part in the study, “People can make lifestyle changes that have big returns on their investment.”

Why are there still so many unsolved issues regarding a condition that affects a quarter of the world’s population? questioned Dr. Delgado-Borrego.

In order to prioritise this situation, which at the moment represents a global public health disaster, a global effort is undoubtedly required.

REFERENCES:

For Alzheimer’s disease medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?generic=192

Is BMI not accurate to predict obesity in many people?

Is BMI not accurate to predict obesity in many people?

Comments 0 Comment

Body mass index (BMI) is a common metric used in healthcare facilities to determine patient health.

It has been frequently criticized for its simplicity of what being healthy actually entails while being used for decades as the standard measurement for health based on body size.

In fact, many people argue that BMI should not be utilized in medical or fitness settings since it is antiquated and inaccurate.

What is BMI?

“BMI” is an acronym for “body mass index.” A Belgian mathematician by the name of Lambert Adolphe Jacques Quetelet created the BMI in 1832.

He created the BMI scale to help governments allocate health and financial resources by swiftly estimating the level of overweight and obesity in a specific community.

Interestingly, Quetelet claimed that BMI was better at capturing the general health of a group than using it to investigate a single individual. Even so, it’s frequently used to gauge people’s health.

The BMI scale is based on a mathematical formula that compares a person’s height in meters squared to their weight in kilograms to determine whether they are a “healthy” weight:

Height (m2) / weight (kg) equals BMI.

Alternately, you can determine BMI by multiplying 703 by the product of your weight in pounds and your height in square inches:

Weight (lbs) x Height (in2) x 703 equals BMI.

A BMI calculator online, like the one offered by the National Institutes of Health, is another option. If you fall within the “normal” weight range, your BMI is calculated and then compared to the BMI scale.

If you don’t fit the definition of “normal” weight, a healthcare practitioner might recommend health and lifestyle adjustments to you.

To more accurately reflect the size and stature of their inhabitants, some nations have adopted the BMI scale. For instance, Asian men and women have been found to have a higher risk of heart disease than non-Asians at lower BMIs.

Even though this can give a healthcare practitioner a quick overview of a person’s health based on weight, it ignores other aspects of a person’s health, including age, sex, race, genetics, fat mass, muscle mass, and bone density.

Is it a reliable sign of health?

The majority of research demonstrates that a person’s risk of chronic disease and early mortality does increase with a BMI lower than 18.5 (“underweight”) or 30.0 or above (“obese”), despite concerns that BMI doesn’t precisely indicate if they are in good health.

A 2017 retrospective research of 103,218 fatalities, for instance, discovered that those with a BMI of 30.0 or higher (referred to as “obese”) had a 1.5–2.7-fold higher chance of dying following a 30-year follow-up.

Another study with 16,868 persons found that those with an “obese” BMI had a 20% higher chance of dying from any cause and heart disease than those with a “normal” BMI.

Additionally, the researchers discovered that people with “underweight” BMIs and “severely obese” or “extremely obese” BMIs died on average 6.7 years and 3.7 years earlier than people with “normal” BMIs.

According to other research, a BMI over 30.0 considerably raises the chance of developing chronic conditions such as type 2 diabetes, heart disease, breathing problems, renal illness, non-alcoholic fatty liver disease, and mobility problems.

A person’s risk of developing metabolic syndrome, heart disease, and type 2 diabetes has also been shown to drop by 5–10% with a BMI reduction.

Many health practitioners can use BMI as a broad indicator of a person’s risk because the majority of studies indicate that obese persons have an elevated chance of developing chronic diseases. But it shouldn’t be the only diagnostic instrument employed.

The BMI as a measure of obesity

The National Health and Nutrition Examination Survey (NHANES), which was conducted from 2011 to 2018, had data on 9,784 participants with an average age of 39.

BMI and body fat % were determined using dual-energy x-ray absorptiometry (DEXA) in the data. BMIs were divided into categories according to ethnicity.

In the end, 36% of individuals were obese, defined as having a BMI of 30 or more. However, 74% of participants were rated as obese based on their body fat percentage.

When body fat % was taken into account, many persons with BMIs between 18.5 and 24.9, which are considered healthy weights, were labelled as obese, including:

  • 27% of Black non-Hispanics
  • 44% of white non-Hispanics
  • 49 percent of Hispanics
  • In Asia, 49%

The finding that non-Hispanic Black people with overweight had 58% lower risk of obesity than non-Hispanic White people struck me as particularly fascinating. Dr. Erkeda de Rouen, a board-certified specialist in family, diversity, and lifestyle medicine who was not involved in the study, said that this might be caused by the regular genetic weight distribution.

A person’s mental health and complex sociological issues like money, access to affordable and nutritious food, food skills and knowledge, and housing conditions are all ignored when a person’s health is solely determined by their BMI.

Drawbacks of BMI

There are many problems with the use of BMI, despite data linking low (below 18.5) and high (30 or above) BMI with elevated health risks.

Disregards other potential health factors

Without taking into account a person’s age, sex, genetics, lifestyle, medical history, or other considerations, BMI just provides a “yes” or “no” answer as to whether they are of “normal” weight.

Relying just on BMI could lead to an overestimation or underestimation of a person’s genuine state of health by excluding other crucial health indicators including cholesterol, blood sugar, heart rate, blood pressure, and inflammation levels.

In addition, BMI employs the same formula for both sexes even though men and women have different body compositions, with males having more muscle mass and less fat mass than women.

Additionally, a person’s body fat mass naturally rises and their muscle mass naturally reduces as they age. Numerous studies have demonstrated that an older adult’s BMI of 23.0-29.9 can be protective against disease and early death.

The premise that all weight is equal

Muscle is denser and takes up less space even though 1 pound or kilogram of muscle weighs the same as 1 pound or kilogram of fat. As a result, someone who is extremely slim but has a lot of muscle may weigh more than average.

For instance, a person with a BMI of 29.5 who weighs 200 pounds (97 kilograms) and is 5 feet 9 inches (175 cm) tall is considered to be “overweight.”

The appearance of two people who are the same height and weight might vary greatly. One can be a bodybuilder with a lot of muscle, whilst the other might have more fat.

If BMI is the only factor taken into account, it is quite easy to mistakenly label someone as “overweight” or “obese” despite their low-fat mass. Therefore, in addition to a person’s weight, it’s necessary to take their bone, muscle, and fat mass into account.

Overlooks the distribution of fat

Even while a higher BMI is associated with worse health outcomes, the distribution of body fat may be more important.

People with a gynoid or pear-shaped body type, also known as those who have fat accumulated in their hips, buttocks, and thighs, are less likely to develop chronic disease than people with an android or apple-shaped body type.

For instance, researchers discovered that those with an apple-shaped fat distribution had a substantially higher risk of all-cause mortality than those with a pear-shaped distribution in a study of 72 studies that included data from more than 2.5 million people.

The authors really emphasized that BMI does not take into account where fat is stored in the body, which might cause a person to be incorrectly classified as being sick or at risk for disease.

Possible weight bias

The medical professional is expected to apply their best judgment, which means that they will take the BMI result and treat each patient as an individual.

However, some medical practitioners simply utilize BMI to assess a patient’s health before making recommendations, which can result in weight prejudice and subpar medical care.

Higher BMI patients more frequently claim that their doctors only address their BMI during appointments for unrelated issues. Serious medical conditions frequently go undiagnosed or are misdiagnosed as weight-related disorders.

In reality, research has shown that those with higher BMIs are less likely to get frequent health checks because of anxiety about being assessed, mistrust of the medical staff, or a bad experience in the past. This can result in delayed diagnoses, care, and treatment.

It might not apply to all populations

Even though BMI is widely used among all adults, it could not adequately reflect the health of some racial and cultural groups.

For instance, multiple studies have demonstrated that, compared to white individuals, people of Asian descent have a higher risk of chronic disease at lower BMI cut-off points.

In truth, the Asian-Pacific BMI recommendations, which offer different BMI cut-off points, were created by the World Health Organisation.

Numerous research has demonstrated that these alternate cut-off points are more effective at identifying Asian populations’ health risks. However, further research is required to compare these cut-off points with Asian Americans who are multigenerational.

Additionally, despite having higher muscle mass and lower fat mass, Black persons may be mistakenly labeled as overweight. This may imply that Black women, in particular, have a greater BMI cutoff criterion for chronic illness risk than those of other races.

Indeed, a 2011 study indicated that Black women were deemed metabolically healthy at cut-off points 3.0 kg/m2 higher than non-Black individuals, which further calls into doubt the applicability of BMI to all racial and ethnic groups.

Last but not least, depending solely on BMI disregards the cultural significance of body size to various communities. Higher fat mass is regarded as desirable and healthier in some cultures. Healthcare practitioners should take into account what each person’s definition of “health” is.

The conclusion

Body mass index (BMI) is a highly debatable health assessment technique used to determine a person’s risk for poor health and body fat.

According to most studies, as BMI rises above the “normal” level, there is an increased risk of developing a chronic illness. Additionally, a low BMI (below 18.5) has been associated with negative health effects.

However, BMI does not take into account other factors that may affect health, including age, sex, fat mass, muscle mass, race, genetics, and medical history. Furthermore, it has been demonstrated that using it as the only predictor of health increases weight bias and health disparities.

BMI is a good place to start, but it shouldn’t be the primary indicator of your health.

REFERENCES:

For Obesity medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?therapy=20

Avoid hypertension and heart disease with Japanese plump.

Avoid hypertension and heart disease with Japanese plump.

Comments 0 Comment

Globally, almost 1.3 million people suffer from high blood pressure. Additionally, the top global risk factor for death is hypertension. One is greatly at risk for developing various forms of heart disease if they have high blood pressure.

Juice concentrate is made from the Japanese plum, according to Temple University researchers. It may aid persons with hypertension who are at risk for cardiovascular disease.

The juice concentrate was also discovered by scientists to help prevent the development of hypertension.

High blood pressure, sometimes referred to as hypertension medically, affects about 1.3 million people worldwide. This makes it the leading cause of mortality.

According to research, having high blood pressure increases the chance of other cardiovascular conditions such as atrial fibrillation, heart failure, stroke, and coronary heart disease.

Currently, Temple University researchers think that the Japanese plum juice concentrate can help lower cardiovascular disease risk in persons with hypertension and may even help prevent high blood pressure. A mouse model was used for the investigation.

Is it possible for Japanese plum to lower blood pressure?

It is customary in Japan to use the word “ume” to refer to the Japanese plum, or Prunus mume, also known as the Japanese apricot.

For use in wine or juice beverages, it is occasionally transformed into an infused juice concentrate. It is known as bainiku-ekisu.

This study’s senior author, Dr. Satoru Eguchi, is a professor in the Cardiovascular Research Centre at the Sol Sherry Thrombosis Research Centre and Centre for Metabolic Disease Research at the Lewis Katz School of Medicine at Temple University. He said the study was motivated by the need for treatments other than prescription medications for hypertension.

Even while they normalise blood pressure, he told us, “current treatments are insufficient to normalise the risk of cardiovascular disease death and incidences like myocardial infarction or stroke.” “Compared to subjects with normal blood pressure, hypertension patients have a higher risk for cardiovascular disease regardless of treatment or drug-induced blood pressure normalisation.”

Researchers claim that prior studies in blood vessel smooth muscle cells shown that bainiku-ekisu helped prevent angiotensin II-induced signals that promote proliferation. Circulatory hormone angiotensin II is recognised to contribute to the emergence of hypertension.

“Angiotensin II is a major hormone (regulating) blood pressure and contributes to the development of hypertension in humans,” stated Dr. Eguchi. In cultured vascular cells, our earlier study showed that it reduced angiotensin II signaling and function. All other fruit extracts failed to change the effects of angiogenic factors in these cells. Our in vitro results, however, were somewhat limited. Thus, we proposed the hypothesis that it might lower blood pressure. Also, the related vascular issues are caused by hypertension in vivo.

Preventing the development of cardiovascular disease

Dr. Eguchi and his team tested their hypotheses on the ume juice concentrate, bainiku-ekisu, using a mouse model for this study.

Angiotensin II was infused into mice to raise their blood pressure. The mice were then given water that either contained bainiku-ekisu or normal water.

Analysis revealed that mice who drank the water with bainiku-ekisu did not develop hypertension.

The Dainik-kiss additionally assisted in shielding their vasculature from the damaging effects of angiotensin II. For instance, mice given the juice concentrate only experienced slight aortic hypertrophy. Whereas mice given normal water experienced severe aortic hypertrophy.

The researchers also discovered that bainiku-ekisu assisted in reducing immune cell levels, which would typically lead to an inflammatory process connected to hypertension.

Additionally, scientists found that bainiku-ekisu prevented the cellular switch from aerobic metabolism to glycolysis which is typically seen in hypertension. This aids in preventing the body from suffering from oxidative stress, which can lead to inflammation, vascular stiffness, and even the emergence of more serious cardiovascular disease.

According to Dr. Eguchi, “Our animal studies indicate that bainiku-ekisu may lower blood pressure in patients with hypertension.” “It is okay to mix with standard treatment. Reducing the amount of medication required to maintain normal blood pressure may also be helpful.

Additionally, he continued, “Taking bainiku-ekisu may help you avoid complications related to hypertension, like heart attack and stroke.”

Previous studies on the health advantages of ume

The Japanese plum is grown on a tree that, like cherry trees, blooms with plum blossoms in the spring, ushering in festive occasions in Japan.

In warm to subtropical climates, Japanese plum trees thrive. The Japanese plum has been grown for thousands of years in China and Japan, but it has also spread to other regions of the world, including sections of the United States.

The Japanese plum has a taste that is more acidic and tart even though it resembles Western plums or apricots in appearance and scent.

The Japanese plum is frequently used to make umeboshi, which is a highly salted and pickled plum that is used as a condiment in conventional Japanese cuisine, in addition to being processed into the infused juice concentrate known as bainiku-ekisu.

Japanese plum has previously been investigated for its potential health advantages. According to earlier studies, ume may aid those who experience the symptoms of gastroesophageal reflux disease (GERD) with their digestive problems.

Other research have revealed that ume contains anti-inflammatory and antioxidant effects and may help prevent obesity and allergy disease.

Additionally, a 2017 study discovered that persons with grade I hypertension who consumed ume extract daily saw an improvement in their diastolic blood pressure.

Study restrictions and conclusions

In addition, we discussed the latest findings with Dr. Rigved Tadwalkar, a board-certified cardiologist at Providence Saint John’s Health Centre in Santa Monica, California.

Although it was conducted on mice, he said, “what’s interesting is that bainiku-ekisu was able to attenuate hypertension and protect against vascular remodelling, which is really quite positive.”

Dr. Tadwalkar did advise caution, however, because there is still much to learn about ume and bainiku-ekisu as potential remedies.

“This is somewhat novel, and mouse models don’t always reflect the complex pathophysiology of human cardiovascular disease,” he said. Therefore, it is evident that human testing would be necessary to establish the effectiveness, safety, and dosage for controlling this.

Dr. Tadwalkar continued, “It does give a potential avenue for these alternative medicines in the therapy of cardiovascular disease. So altogether, it’s encouraging, but obviously, I approach the subject with a little bit of scepticism.”

Dr. Tadwalkar concurred, saying it’s critical to look into alternative treatments for cardiovascular illnesses.

“Today’s patient is looking for a range of options and they want to have a specific treatment plan that’s tailored to their needs and circumstances,” he added. “This offers a slightly more individualized approach. And it can include all of the popular holistic treatments, including dietary adjustments, lifestyle changes, and all-natural cures combined.

“I think it allows patients to feel more empowered because they can take a little bit more of an active role in their own care,” Dr. Tadwalkar continued. According to my observations, patients are frequently much more likely to be interested in conventional medication when they may adopt a complementary strategy that encourages the use of alternative medicines.

REFERENCES:

For Heart disease medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?cPath=77_99

Can a common diabetes drug could lower COVID risk?

Can a common diabetes drug could lower COVID risk?

Comments 0 Comment

Metformin, a common diabetes drug, was tested by researchers to see if it could stop lengthy COVID.

Metformin can cut down lengthy COVID diagnosis by 40%, according to their research. If these results apply to the general population, more research is required.

Long COVID is characterised by continuous health issues that continue even after a COVID-19 diagnosis and cannot be attributed to any other causes.

The duration of symptoms might range from weeks to years. Long COVID has been associated with more than 200 symptoms, from exhaustion and nausea to memory loss, stomach discomfort, and dyspnea or difficulty breathing.

What causes lengthy COVID has been the subject of several different theories. Mechanistic research, however, are still in their early stages. The illness is still in its early stages of development, as are treatments and prevention strategies.

The coronavirus that causes COVID-19, SARS-CoV-2, is currently the greatest strategy to prevent lengthy COVID, according to the Centres for Disease Control and Prevention (CDC). This can be done, for example, by staying current on vaccines.

The quality of life and reduction of long-term handicap among patients could be improved by measures to prevent protracted COVID after contracting COVID-19.

Three widely used medications were recently investigated for their ability to prevent extended COVID.

They discovered that lengthy COVID was considerably less likely to occur in participants taking metformin compared to those taking a placebo. A common diabetes drug called metformin raises insulin sensitivity to reduce blood sugar levels.

Metformin may reduce the occurrence of long-term COVID.

It was a phase 3 randomised clinical trial. 1,126 individuals with COVID-19 symptoms and a positive PCR or antigen test for this viral infection, ranging in age from 30 to 85 years, were enrolled by the researchers.

The patients had either fat or overweight, which increased their likelihood of developing severe COVID even though they were not hospitalised for COVID-19.

The individuals were randomly assigned to one of six groups, each of which received a different dosage of metformin for 14 days, ivermectin for 3 days, fluvoxamine for 14 days, and placebo. Fluvoxamine is used to treat obsessive-compulsive disorder (OCD), and ivermectin is an antiparasitic medication.

For ten months, the subjects were monitored. Throughout the follow-up period, they were questioned multiple times about whether they had obtained a medical provider’s diagnosis of extended COVID.

After 300 days of follow-up, 8.3% of patients overall reported a lengthy COVID diagnosis. Only 6.3% of patients who took metformin, as opposed to 10.4% of those who received a placebo, experienced lengthy COVID.

In comparison to a placebo, ivermectin and fluvoxamine had no effect on the incidence of long-term COVID.

The Safe Drug Metformin Has Proven Antiviral Effects

Based on the knowledge that metformin is safe and has proven anti-inflammatory and antiviral capabilities, the study team pursued it as a potential long-COVID treatment.

Hector Fabio Bonilla, MD, is the co-director of the Stanford Post-Acute COVID-19 Syndrome Clinic and has observed laboratory test outcomes that support metformin’s potential to lessen antiviral and anti-inflammatory activities that can result in thrombosis (when blood clots block blood arteries) and lung harm.

Dr. Bonilla, who is also a clinical associate professor of infectious diseases at Stanford University, adds, “Plus, this drug is relatively safe, with no increased risk of hypoglycemia low blood sugar and no increased risk of lactic acidosis lactic acid buildup related to low oxygen levels.” There is no need to cease taking metformin before surgery because it is safe to take during pregnancy, breastfeeding, and in individuals with renal failure.

Underlying processes

We discussed how metformin may have decreased long COVID risk with Dr. Mark Guido, an endocrinologist from Novant Health Forsyth Endocrine Consultants in Winston Salem, NC, who was not involved in the study.

It is difficult to say because we still don’t fully comprehend extended COVID, but it might be connected to lowering inflammation, he suggested. Additionally, metformin has been demonstrated to potentially lessen severe COVID and to halt the reproduction of the [SARS-CoV-2] virus in a lab setting, both of which may also be involved.

We also discussed how metformin may have decreased long COVID risk with Dr. Daniel Kim, a board-certified family doctor of Medical Offices of Manhattan who was not part in the study.

He concurred that it is still unknown exactly how certain things work. Nevertheless, he added that earlier research suggests that metformin has an antiviral effect by preventing viral multiplication.

Do all people fall within the study’s conclusions?

Dr. Guido responded to a question concerning the study’s limitations by saying, “Since our understanding of long COVID is still evolving, there were no specific diagnostic criteria used to determine who did or did not qualify as having long COVID.”

“The trial was also restricted to participants who were overweight or obese and were not currently on metformin. It is unknown if people who are already on metformin for other disorders or who have a normal weight will experience the same effects from metformin,” he added.

The trial was limited to examining the use of metformin to stop long-term COVID during a patient’s initial COVID infection. It is uncertain whether metformin would guard against extended COVID if a patient had previously contracted COVID-19, he continued.

According to Dr. Kim, “It is also unknown if [the results] can be generalized to early outpatient treatment of COVID-19 patients who were previously diagnosed with COVID-19 infection.”

Avoiding prolonged COVID

The results, according to Dr. Guido, could have a significant impact on short COVID prevention.

“Long COVID is turning into a public health emergency. Long-term public health would greatly benefit if it could be successfully decreased by a cheap, well-tolerated, and easily accessible medicine like metformin,” he said.

Dr. Kim concurred that the results are encouraging. He did point out that additional research is required to evaluate whether metformin is as effective for the broader populace.

REFERENCES:

For Diabetes medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?therapy=13